Skip to main content

Emblaveo FDA Approval History

Last updated by Judith Stewart, BPharm on Feb 9, 2025.

FDA Approved: Yes (First approved February 7, 2025)
Brand name: Emblaveo
Generic name: avibactam and aztreonam
Dosage form: Lyophilized Powder for Injection
Company: AbbVie Inc.
Treatment for: Intraabdominal Infection

Emblaveo (aztreonam and avibactam) is a monobactam antibacterial and beta-lactamase inhibitor combination used for the treatment of complicated intra-abdominal infections.

Development timeline for Emblaveo

DateArticle
Feb  7, 2025Approval FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections
Jun  1, 2023Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Aztreonam-Avibactam (ATM-AVI) Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.